Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849

Mapping and quantifying mammalian transcriptomes by RNA-Seq

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696

Primer3—new capabilities and interfaces

Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool

Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Path towards mRNA delivery for cancer immunotherapy from bench to bedside

Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33

Advances and challenges in immunotherapy of small cell lung cancer

Guo, H., Li, L., & Cui, J. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.01.13 · Cited by 30

Trial watch: DNA-based vaccines for oncological indications

Pierini, S., Perales-Linares, R. F., Uribe‐Herranz, M., Pol, J. G., Zitvogel, L., Kroemer, G., Facciabene, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398878 · Cited by 29

Stochastic modeling of tumor progression and immune evasion

George, J. T., & Levine, H. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.09.012 · Cited by 27

Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity

Mensali, N., Grenov, A., Pati, N. B., Dillard, P., Myhre, M. R., Gaudernack, G., Kvalheim, G., Inderberg, E. M., Bakke, O., & Wälchli, S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1558663 · Cited by 32

Retinol Saturase: More than the Name Suggests

Weber, P., Flores, R. E., Kiefer, M. F., & Schupp, M. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.007 · Cited by 31

CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells

Yamauchi, T., Hoki, T., Oba, T., Kajihara, R., Attwood, K. M., Cao, X., & Ito, F. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02969-6 · Cited by 29

Role of CD4+CD25+FOXP3+TRegcells on tumor immunity

Hariyanto, A. D., Permata, T. B. M., & Gondhowiardjo, S. A. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1975228 · Cited by 31

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer

McCann, K. J., Witzleben, A. V., Thomas, J., Wang, C., Wood, O., Singh, D. K., Boukas, K., Bendjama, K., Silvestre, N., Nielsen, F. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003821 · Cited by 30

COVID‐19: Clinical status of vaccine development to date

Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

LoRusso, P. M., Schalper, K. A., & Sosman, J. A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12847 · Cited by 30

Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors

Shi, Y., Jing, B., & Xi, R. (2023) · Genome biology · doi:10.1186/s13059-023-03005-9 · Cited by 31

The role and participation of immune cells in the endometrial tumor microenvironment

Dey, D. K., Krause, D., Rai, R., Choudhary, S., Dockery, L., & Chandra, V. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108526 · Cited by 29

Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives

Farooq, M. U., Lawrie, C. H., & Deng, N. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150356 · Cited by 30

Adjuvant immunotherapy for melanoma patients: progress and opportunities

Sussman, T. A., & Ott, P. A. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102962 · Cited by 30

Vaccines for cancer prevention: exploring opportunities and navigating challenges

Graciotti, M., & Kandalaft, L. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01081-5 · Cited by 30

A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations

Toor, J. S., Rao, A. A., McShan, A. C., Yarmarkovich, M., Nerli, S., Yamaguchi, K., Madejska, A. A., Nguyen, S., Tripathi, S. M., Maris, J. M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00099 · Cited by 28

Melanoma vaccines: clinical status and immune endpoints

Maurer, D. M., Butterfield, L. H., & Vujanovic, L. N. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000535 · Cited by 32

A strategy for generating cancer-specific monoclonal antibodies to aberrantO-glycoproteins: identification of a novel dysadherin-Tn antibody

Steentoft, C., Fuhrmann, M., Battisti, F., Coillie, J. V., Madsen, T. D., Campos, D., Halim, A., Vakhrushev, S. Y., Joshi, H. J., Schreiber, H. W., et al. (2019) · Glycobiology · doi:10.1093/glycob/cwz004 · Cited by 30

Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries

Abdel-Hakeem, M. S. (2019) · Viruses · doi:10.3390/v11020106 · Cited by 29

Vaccine Strategy in Melanoma

Kwak, M., Leick, K. M., Melssen, M. M., & Slingluff, C. L. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.003 · Cited by 29

ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection

Li, Y., Wang, G., Tan, X., Ouyang, J., Zhang, M., Song, X., Liu, Q., Leng, Q., Chen, L., & Xie, L. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0683-4 · Cited by 29

Empirical and Rational Design of T Cell Receptor-Based Immunotherapies

Jones, H. F., Molvi, Z., Klatt, M. G., Dao, T., & Scheinberg, D. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585385 · Cited by 28

Tumor microenvironment-triggered in situ cancer vaccines inducing dual immunogenic cell death for elevated antitumor and antimetastatic therapy

Ding, B., Zheng, P., Li, D., Wang, M., Jiang, F., Wang, Z., Ma, P., & Lin, J. (2021) · Nanoscale · doi:10.1039/d1nr02018h · Cited by 29

Distinct signatures of codon and codon pair usage in 32 primary tumor types in the novel database CancerCoCoPUTs for cancer-specific codon usage

Meyer, D., Kames, J. M., Bar, H., Komar, A. A., Alexaki, A., Ibla, J. C., Hunt, R., Santana-Quintero, L. V., Golikov, A., DiCuccio, M. N., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00935-6 · Cited by 31

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Abbas, H. A., Alaniz, Z., Mackay, S., Cyr, M., Zhou, J., Issa, G. C., Alfayez, M., Matthews, J. A., Kornblau, S. M., Jabbour, E. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004583 · Cited by 30

Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade

Gorzo, A., Galoș, D., Volovăț, S. R., Lungulescu, C. V., Burz, C. C., & Sur, D. G. (2022) · Life · doi:10.3390/life12020229 · Cited by 30

In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer

Lu, L., Ma, W., Johnson, C. H., Khan, S. A., Irwin, M. L., & Pusztai, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.048 · Cited by 30

mRNA vaccination in breast cancer: current progress and future direction

Jiang, X., & Liu, Q. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04805-z · Cited by 29

Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses

Shukla, G. S., Sun, Y., Pero, S. C., Sholler, G. L. S., & Krag, D. N. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.06.009 · Cited by 29

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice

Joe, P. T., Christopoulou, I., Hoecke, L. V., Schepens, B., Ysenbaert, T., Heirman, C., Thielemans, K., Saelens, X., & Aerts, J. L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1991-3 · Cited by 29

Leveraging mRNA technology for antigen based immuno-oncology therapies

Floudas, C. S., Sarkizova, S., Ceccarelli, M., & Zheng, W. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010569 · Cited by 32

Advances in Personalized Cancer Vaccine Development: AI Applications from Neoantigen Discovery to mRNA Formulation

Kong, H. (2025) · BioChem · doi:10.3390/biochem5020005 · Cited by 31

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Enhancing mucosal immunity by transient microbiota depletion

Becattini, S., Littmann, E. R., Seok, R., Amoretti, L. A., Fontana, E., Wright, R. J., Gjonbalaj, M., Leiner, I. M., Plitas, G., Hohl, T. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18248-4 · Cited by 28

Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach

Maine, C. J., Richard, G., Spasova, D. S., Miyake-Stoner, S. J., Sparks, J., Moise, L., Sullivan, R. P., Garijo, O., Choz, M., Crouse, J. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.027 · Cited by 30

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma

Welters, M. J. P., Santegoets, S. J. A. M., & van der Burg, S. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.545385 · Cited by 27

Advances in mRNA-based drug discovery in cancer immunotherapy

Trani, C. A. D., Fernández-Sendin, M., Cirella, A., Segués, A., Olivera, I., Bolaños, E., Melero, I., & Berraondo, P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1978972 · Cited by 28

MATHLA: a robust framework for HLA-peptide binding prediction integrating bidirectional LSTM and multiple head attention mechanism

Ye, Y., Wang, J., Xu, Y., Wang, Y., Pan, Y., Song, Q., Liu, X., & Wan, J. (2021) · BMC Bioinformatics · doi:10.1186/s12859-020-03946-z · Cited by 28

Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice

Schmidt, M., & Heimes, A.-S. (2021) · Cancers · doi:10.3390/cancers13194883 · Cited by 28

Neoantigens and their potential applications in tumor immunotherapy (Review)

Fang, X., Guo, Z., Liang, J., Wen, J., Liu, Y., Guan, X., & Hong, L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13208 · Cited by 29

A synthetic DNA template for fast manufacturing of versatile single epitope mRNA

de Mey, W., Schrijver, P. D., Autaers, D., Pfitzer, L., Fant, B., Locy, H., Esprit, A., Lybaert, L., Bogaert, C., Verdonck, M., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.021 · Cited by 28

KEYNOTE – D36: Personalized Immunotherapy with a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma

Long, G. V., Ferrucci, P. F., Khattak, A., Meniawy, T. M., Ott, P. A., Chisamore, M. J., Trolle, T., Hyseni, A., & Heegaard, E. D. (2022) · Future Oncology · doi:10.2217/fon-2022-0694 · Cited by 28

Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy

Meng, L., Teng, Z., Yang, S., Wang, N., Guan, Y., Chen, X., & Liu, Y. (2023) · Nanoscale · doi:10.1039/d2nr07071e · Cited by 28

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022

Chen, Y., Chen, Y., Tan, S., Zheng, Y., Liu, S., Zheng, T., Mi, Y., Lin, S., Yang, C., & Li, W. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2186684 · Cited by 28

Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response

Hogan, M. J., Maheshwari, N., Begg, B. E., Nicastri, A., Hedgepeth, E. J., Muramatsu, H., Pardi, N., Miller, M. A., Reilly, S. P., Brossay, L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01644-5 · Cited by 28

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

Iiizumi, S., Ohtake, J., Murakami, N., Kouro, T., Kawahara, M., Isoda, F., Hamana, H., Kishi, H., Nakamura, N., & Sasada, T. (2019) · Cancers · doi:10.3390/cancers11020266 · Cited by 30

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance

Pelizzaro, F., Farinati, F., & Trevisani, F. (2023) · Biomedicines · doi:10.3390/biomedicines11041020 · Cited by 28

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer

Baleeiro, R. B., Liu, P., Chard, L. S., Gioia, C. D., Nagano, A., Cutmore, L. C., Wang, J., Chelala, C., Nyambura, L. W., Walden, P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007336 · Cited by 29

The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines

Chakraborty, C., Majumder, A., Bhattacharya, M., Chatterjee, S., & Lee, S. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100177 · Cited by 29

Multiomic profiling of chronically activated CD4+ T cells identifies drivers of exhaustion and metabolic reprogramming

Lawton, M. L., Inge, M. M., Blum, B. C., Smith-Mahoney, E. L., Bolzan, D., Lin, W., McConney, C., Porter, J., Moore, J., Youssef, A., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002943 · Cited by 25

mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment

Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30

Peptide-Major Histocompatibility Complex Class I Binding Prediction Based on Deep Learning With Novel Feature

Zhao, T., Cheng, L., Zang, T., & Hu, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01191 · Cited by 28

Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer

Naciūtė, M., Niemi, V., Kemp, R. A., & Hook, S. M. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.04.020 · Cited by 27

Killing the “BAD”: Challenges for immunotherapy in pancreatic cancer

Li, T., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188384 · Cited by 27

Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Chen, H., Yang, G., Xiao, J., Zheng, L., You, L., & Zhang, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.011 · Cited by 30

A biomimetic antitumor nanovaccine based on biocompatible calcium pyrophosphate and tumor cell membrane antigens

Li, M., Qin, M., Song, G., Deng, H., Wang, D., Wang, X., Dai, W., He, B., Zhang, H., & Zhang, Q. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.06.006 · Cited by 27

Tuberculosis–Cancer Parallels in Immune Response Regulation

Bickett, T. E., & Karam, S. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176136 · Cited by 29

A Systematic, Unbiased Mapping of CD8+ and CD4+ T Cell Epitopes in Yellow Fever Vaccinees

Stryhn, A., Kongsgaard, M., Rasmussen, M., Harndahl, M. N., Østerbye, T., Bassi, M. R., Thybo, S., Gabriel, M., Hansen, M. B., Nielsen, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01836 · Cited by 26

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy

Bai, P., Li, Y., Zhou, Q., Xia, J., Wei, P., Deng, H., Wu, M., Chan, S. K., Kappler, J. W., Zhou, Y., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1868130 · Cited by 27

Neoantigen landscape in metastatic nasopharyngeal carcinoma

Lin, M. F., Zhang, X., You, R., Yang, Q., Zou, X., Yu, K., Liu, Y., Zou, R., Hua, Y., Huang, P., et al. (2021) · Theranostics · doi:10.7150/thno.53229 · Cited by 27

Sensitive and Quantitative Detection of MHC-I Displayed Neoepitopes Using a Semiautomated Workflow and TOMAHAQ Mass Spectrometry

Pollock, S. B., Rose, C. M., Darwish, M., Bouziat, R., Delamarre, L., Blanchette, C., & Lill, J. R. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100108 · Cited by 29

HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles

Bauzá‐Martinez, J., Heck, A. J. R., & Wu, W. (2021) · Communications Biology · doi:10.1038/s42003-021-02364-y · Cited by 26

A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells

Veatch, J. R., Singhi, N., Srivastava, S., Szeto, J. L., Jesernig, B. L., Stull, S. M., Fitzgibbon, M., Sarvothama, M., Yechan-Gunja, S., James, S. E., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144195 · Cited by 28

Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles

Caproni, E., Corbellari, R., Tomasi, M., Isaac, S. J., Tamburini, S., Zanella, I., Grigolato, M., Gagliardi, A., Benedet, M., Baraldi, C., et al. (2023) · Cancers · doi:10.3390/cancers15133328 · Cited by 27

Fusobacterium nucleatum carcinogenesis and drug delivery interventions

Chen, Z., & Huang, L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115319 · Cited by 27

Non‐viral gene delivery for cancer immunotherapy

Wang, W., Saeed, M., Zhou, Y., Yang, L., Wang, D., & Yu, H. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3092 · Cited by 29

A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer

Miller, A. M., Koşaloğlu‐Yalçın, Z., Westernberg, L., Montero, L., Bahmanof, M., Frentzen, A., Lanka, M., Premlal, A. L. R., Seumois, G., Greenbaum, J., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9905 · Cited by 28

Stem-like CD8+ T cells in cancer

Steiner, C., Denlinger, N., Huang, X., & Yang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1426418 · Cited by 28

mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy

Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27

Advancements in Cancer Treatment: Harnessing the Synergistic Potential of Graphene-Based Nanomaterials in Combination Therapy

Keyvani, A. H., Mohammadnejad, P., Pazoki–Toroudi, H., Gilabert, I. P., Chu, T., Manshian, B. B., Soenen, S. J., & Sohrabi, B. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c15536 · Cited by 26

Methods for improving the immunogenicity and efficacy of cancer vaccines

Pilla, L., Ferrone, S., & Maccalli, C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1485649 · Cited by 27

Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen

Vigneron, N., Ferrari, V., den Eynde, B. J. V., Cresswell, P., & Leonhardt, R. M. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701479 · Cited by 26

Immunotherapy in Older Adults with Cancer

Godby, R. C., Johnson, D. B., & Williams, G. R. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0806-2 · Cited by 28

Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine

Boudousquié, C., Boand, V., Lingre, E., Dutoit, L., Balint, K., Danilo, M., Harari, A., Gannon, P. O., & Kandalaft, L. E. (2020) · Vaccines · doi:10.3390/vaccines8010025 · Cited by 26

PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses

Tian, H., Kang, Y., Song, X., Xu, Y., Chen, H., Gong, X., Zhang, W., Xu, Y., Xia, X., Gao, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.024 · Cited by 26

Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition

Lione, L., Salvatori, E., Petrazzuolo, A., Massacci, A., Maggio, R., Conforti, A., Compagnone, M., Aurisicchio, L., Ciliberto, G., & Palombo, F. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1898832 · Cited by 26

Emerging targets for anticancer vaccination: IDH

Platten, M., Bunse, L., & Wick, W. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100214 · Cited by 26

TSNAD v2.0: A one-stop software solution for tumor-specific neoantigen detection

Zhou, Z. M., Wu, J., Ren, J.-N., Chen, W., Zhao, W., Gu, X., Chi, Y., He, Q., Yang, B., Wu, J., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.016 · Cited by 28

Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines

Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 26

T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles

Hensen, L., Illing, P. T., Rowntree, L. C., Davies, J., Miller, A., Tong, S. Y. C., Habel, J. R., van de Sandt, C. E., Flanagan, K. L., Purcell, A. W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812393 · Cited by 29

Application of mRNA Technology in Cancer Therapeutics

Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27

Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity

Liu, W., Alameh, M., Yang, J. F., Xu, J. R., Lin, P. J. C., Tam, Y. K., Weissman, D., & You, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314504 · Cited by 33

Research Progress of Immunotherapy for Gastric Cancer

Zhang, Z., Liu, N., & Sun, M. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221150555 · Cited by 26

Smart delivery of vaccines

Melief, C. J. M. (2018) · Nature Materials · doi:10.1038/s41563-018-0085-6 · Cited by 26

Neoepitopes-based vaccines: challenges and perspectives

Alcazer, V., Bonaventura, P., Tonon, L., Valsesia‐Wittmann, S., Caux, C., & Depil, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.011 · Cited by 27

Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain

Longino, N. V., Yang, J., Iyer, J. G., Ibrani, D., Chow, I., Laing, K. J., Campbell, V. L., Paulson, K. G., Kulikauskas, R. M., Church, C. D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0103 · Cited by 28

The Interplay between Tumour Microenvironment Components in Malignant Melanoma

Amălinei, C., Grigoraş, A., Lozneanu, L., Căruntu, I.-D., Giuşcă, S. E., & Balan, R. A. (2022) · Medicina · doi:10.3390/medicina58030365 · Cited by 27

Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens

Chi, W.-Y., Hu, Y., Huang, H., Kuo, H., Lin, S., Kuo, C.-T. J., Tao, J., Fan, D., Huang, Y.-M., Wu, A. A., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01082-x · Cited by 27

Leveraging Artificial Intelligence for Neoantigen Prediction

Zeng, J., Lin, Z., Zhang, X., Zheng, T., Xu, H., & Liu, T. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2553 · Cited by 26

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial

Saxena, M., Anker, J. F., Kodysh, J., O’Donnell, T. J., Kaminska, A. M., Meseck, M. L., Hapanowicz, O., Niglio, S. A., Salazar, A. M., Shah, H., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00966-7 · Cited by 25

Impact of tail unsaturation in ionizable lipids on mRNA delivery efficiency and immunogenicity of lipid nanoparticles

Ge, X., He, Z., Yang, H., Pan, X., Yan, L., Shi, Y., Chen, Y., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113906 · Cited by 25

Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics

Vizirianakis, I. S., Miliotou, Α. N., Mystridis, G. A., Andriotis, E. G., Andreadis, I. I., Papadopoulou, L. C., & Fatouros, D. G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1605828 · Cited by 25

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade

Zhang, M., Liu, K., & Wang, M. (2019) · RSC Advances · doi:10.1039/c9ra04590b · Cited by 26

Neoantigen prediction in human breast cancer using RNA sequencing data

Hashimoto, S., Noguchi, E., Bando, H., Miyadera, H., Morii, W., Nakamura, T. K., & Hara, H. (2020) · Cancer Science · doi:10.1111/cas.14720 · Cited by 25

Personal Neoantigen Vaccines for the Treatment of Cancer

Shetty, K. S., & Ott, P. A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060820-111701 · Cited by 27

Nanotechnology synergized immunoengineering for cancer

Chauhan, D. S., Dhasmana, A., Laskar, P., Prasad, R., Jain, N. K., Srivastava, R., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.010 · Cited by 27

Immunogenomics in personalized cancer treatments

Kiyotani, K., Toyoshima, Y., & Nakamura, Y. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00950-w · Cited by 25

Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials

Ingels, J., Cock, L. D., Mayer, R. L., Devreker, P., Weening, K., Heyns, K., Lootens, N., Smet, S. D., Brusseel, M., Munter, S. D., et al. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.08.005 · Cited by 25

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers

Anderson, K. S., Erick, T. K., Chen, M., Daley, H., Campbell, M., Colson, Y. L., Mihm, M. C., Zakka, L. R., Hopper, M., Barry, W. T., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06562-y · Cited by 25

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Miller, M., Loquai, C., Kloke, B., Attig, S., Bidmon, N., Bolte, S., Bukur, V., Derhovanessian, E., Diekmann, J., Filbry, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct022

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Fritsch, E. F., Hacohen, N., & Wu, C. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-pr02

Personalized melanoma vaccines

Kelly, P. N. (2017) · Science · doi:10.1126/science.357.6353.769-b